Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096560 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT04096560 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 97 participants.
The verdict
NCT04096560, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The main aims of the study are: * To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. * To check what dose range provides adequate relief of narcolepsy symptoms. * To check how much TAK-994 stays in the blood of participants, over time. The study will have 4 parts. Participants can only join 1 of the parts. A. Participants with type 1 narcolepsy will take either TAK-994 or placebo tablets for 28 days. A placebo looks just like TAK-994 but will not have any medicine in it. B. Participants with type 1 narcolepsy will take 1 of 3 doses of TAK-994 or placebo tablets for 56 days. C. Participants with type 1 narcolepsy in China only will take TAK-994 or placebo tablets for 56 days. D. Participants with type 2 narcolepsy will take either TAK-994 or placebo tablets for 28 days.
Interventions
- DRUG Placebo
- DRUG TAK-994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2020-05-27 |
| Est. Completion | 2021-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096560
The ClinicalTrials.gov registry entry for NCT04096560 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04096560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04096560 about?
NCT04096560 is a clinical study titled "A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy". The main aims of the study are: * To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. * To check what dose range provides adequate relief of narcolepsy symptoms. * To check how much TAK-994 stays in the blood of participants, over time. The study will h...
What is the current status of trial NCT04096560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2020-05-27. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT04096560?
The interventions under investigation include: Placebo (DRUG), TAK-994 (DRUG).
Who is sponsoring clinical trial NCT04096560?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.